



The Office of the National Coordinator for
Health Information Technology



Behavioral Health eMeasures Technical Expert Panel

In-Person Meeting

August 9, 2012

Putting the **I** in Health **IT**
www.HealthIT.gov



Welcome and Introductions



- Community Members
- Federal Staff
- Project Core Team

Goals and Objectives



- Review TEP Phase 1 Recommendations
- Begin TEP Phase 2 Initiatives
 - Depression Trended Outcome Measure
 - Drug Use/Prescription Drug Misuse Measure
- Advance Understanding
 - Comorbidities of Physical and Psychiatric Conditions
 - Meaningful Use in Behavioral Health Settings
 - BH CQM Implementation Challenges
 - Composite Measure Development Process

AGENDA - Morning



TIME	TOPIC	PRESENTER
8:30a – 9:00a	Registration	
9:00a – 9:10a	Welcome and Introductions <ul style="list-style-type: none"> • Community Members • Subgroup Federal Staff • Project Core Team 	TEP Sponsor Leads: Maureen Boyle/SAMHSA Lauren Richie/ONC
	Goals and Schedule	
9:10a – 9:40a	Opening Remarks Comorbidities of Physical and Psychiatric Conditions	Caroline Carney Doebbeling, MD, CMO, MDwise, Inc., Medicaid Managed Care, Indiana Former Medical Director, Indiana Medicaid Program
9:40a – 10:00a	TEP Phase 1 Recommendations Overview	Maureen Boyle/SAMHSA Lauren Richie/ONC MITRE
10:00a – 10:15a	BREAK	All
10:15a – 11:30a	BREAK-OUT SESSIONS - Morning <ul style="list-style-type: none"> • Track 1: Depression (move to Room 733D) • Track 2: Drug Use/ Prescription Drug Misuse (remain in Room 705A) 	Facilitators: 1: Maureen Boyle 2: Lauren Ritchie
11:30a – 12:00p	BREAK/OBTAIN LUNCH Groups Escorted to HHS Cafe	All

AGENDA - Afternoon



TIME	TOPIC	PRESENTER
12:00p – 1:00p	Lunch Presentation Behavioral Health Clinical Quality Reporting - the Provider Perspective: Incorporating Quality Measures into Practice	Speakers: Kevin Larsen, MD HHS/ONC Frank Ghinassi, PhD, ABPP University of Pittsburgh
1:00p – 2:15p	BREAK-OUT SESSIONS - Afternoon <ul style="list-style-type: none"> Track 1: Depression (move to Room 733D) Track 2: Drug Use/Prescription Drug Misuse (remain in Room 705A) 	Facilitators: 1: Maureen Boyle 2: Lauren Ritchie
2:15p – 2:45p	REPORT-OUT	All
2:45p – 3:00p	BREAK	
3:00p – 3:30p	Plenary Session: Composite Measure Development Process and Challenges	Karen Pace National Quality Forum
3:30p – 4:30p	Composite Measure Development Exercise	All
4:30p	ADJOURN	



Caroline Carney Doebbeling, MD

CMO, MDwise, Inc.

Indiana Medicaid Managed Care Plan

Former Medical Director, Indiana Medicaid
Program



TEP Phase 1 Review

White Paper

Executive Summaries



Review	Results
Meaningful Use Stage 1—Final Rule	No measures selected for this clinical domain
Meaningful Use Stage 2 (NPRM)	No measures selected for this clinical domain
Project Phase 1 eSpecified Measures	2 measures identified for this clinical domain
Non-endorsed Measures (AHRQ Database)	No measures identified for this clinical domain
Clinical Evidence	195 preliminary citations and 21 guidance/protocol-related documents identified to inform a focused literature search 181 citations identified for this clinical domain and categorized by broad topic areas (see white paper for topics)

Recommendations

- Further enhancement of clinical measure NQF 1399 to leverage for development of an Autism-specific screening
- Development of a CQM for universal screening or a suite of screenings of Autism appropriate for diagnosing the disorder across the life span



Review	Results
Meaningful Use Stage 1—Final Rule	1 measure related to this clinical domain
Meaningful Use Stage 2 (NPRM)	2 proposed measures related to this clinical domain
Project Phase 1 eSpecified Measures	5 measures related to this clinical domain
Non-endorsed Measures (AHRQ Database)	4 measures related to this clinical domain (1 defined as “yes;” 3 defined as “maybe”)
Clinical Evidence	79 articles covering five broad areas: <ul style="list-style-type: none"> • General Screening, Brief Intervention, and Referral to Treatment (SBIRT) results in primary care • Implementation • Screening tools • Youth • Medication and technology-assisted treatment



Recommendations

- Adoption of NQF Measures—eSpecified but not in MU Stage 2 NPRM
 - NQF 1406—Risky Behavior Assessment or Counseling by Age 13 Years
 - NQF 1507—Risky Behavior Assessment or Counseling by Age 18 Years
 - NQF 1661—SUB-1 Alcohol Use Screening
 - NQF 1663—SUB-2 Alcohol Use Brief Intervention Provided or Offered and SUB-2a Alcohol Use Brief Intervention
- Further investigation for endorsement and eSpecification of Agency for Healthcare Research and Quality (NCQA) measures:
 - National Quality Measures Clearinghouse (NQMC) 004458 (Physician Consortium for Performance Improvement [PCPI])
- Future development of Clinical Quality Measures for:
 - Early screening of youth
 - Patient-administered screening tools

Drug Use



Review	Results
Meaningful Use Stage 1—Final Rule	1 measure related to this clinical domain
Meaningful Use Stage 2 (NPRM)	2 proposed measures related to this clinical domain
Project Phase 1 eSpecified Measures	3 measures related to this clinical domain
Non-endorsed Measures (AHRQ Database)	4 measures related to this clinical domain (one defined as “maybe;” and 3 defined as “yes”)
Clinical Evidence	<p>82 articles covering 10 broad areas:</p> <ul style="list-style-type: none"> • Review Studies • Guidelines • Drug Use Screening Tools • Drug Use Screening/Intervention/Treatment Outcomes • Treatment Outcomes—Motivational Interviewing • Drug Use Screening/Intervention/Treatment—Adolescent • Drug Use Screening/Intervention/Treatment—American Indian/Alaska Native • Drug Use Screening/Intervention/Treatment—Patients with Psychiatric Disorder • Physician Training • Drug Use and Electronic Health Records



Recommendations

- Adoption of NQF Measures—eSpecified but not in Meaningful Use Stage 2 NPRM
 - NQF 1406—Risky Behavior Assessment or Counseling by Age 13 Years
 - NQF 1507—Risky Behavior Assessment or Counseling by Age 18 Years
- Further investigation for endorsement and eSpecification of measures from the AHRQ database identified by their National Quality Measures Clearinghouse (NQMC) numbers and measure stewards below:
 - National Quality Measures Clearinghouse (NQA) 004006 (American Psychiatric Association [APA]/National Committee for Quality Assurance [NCQA]/Physician Consortium for Performance Improvement[PCPI])
 - NQMC 004208 (APA/NCQA/PCPI)
 - NQMC 006322 (The Joint Commission [TJC])
- Future development of CQMs for self-administered screening tools for drug use



Review	Results
Meaningful Use Stage 1—Final Rule	1 measure related to this clinical domain
Meaningful Use Stage 2 (NPRM)	11 proposed measures related to this clinical domain
Project Phase 1 eSpecified Measures	8 measures related to this clinical domain
Non-endorsed Measures (AHRQ Database)	10 measures related to this clinical domain
Clinical Evidence	197 articles covering 6 broad areas: <ul style="list-style-type: none"> • Electronic Health/Medical Records + Screening and Follow Up • Patient’s Self-Report/Patient Recorded Outcomes (PRO) • Patient Health Questionnaire-9 • Trendable/Tracking • Physician vs. Psychiatrist • Positive Screen → Referral/Treatment



Recommendations

- Adoption of NQF Measures:
 - NQF 0418 if not part of MU Stage 2 Final Rule
- Further investigation for endorsement and eSpecification of measures from the Agency for Healthcare Research and Quality (AHRQ) database identified by their National Quality Measures Clearinghouse (NQMC) numbers and measure stewards below:
 - NQMC 005108 British Medical Association
 - NQMC 006171 Institute for Clinical Systems Improvement (ICSI)
 - NQMC 006168 (ICSI)
 - NQMC 006169 (ICSI)
 - NQMC 006170 (ICSI)
 - NQMC 006167 (ICSI)
- Future development of CQMs for trending of depression outcome variables



Review	Result
Meaningful Use Stage 1—Final Rule	No measures related to this clinical domain
Meaningful Use Stage 2 (NPRM)	2 proposed measures related to this clinical domain
Project Phase 1 eSpecified Measures	2 measures related to this clinical domain
Non-endorsed Measures (AHRQ Database)	1 measure related to this clinical domain
Clinical Evidence	<p>60 articles covering eight broad areas:</p> <ul style="list-style-type: none"> • Suicide Risk—Physician Practice/Training • Suicide Risk Assessment—All Categories • Depression and Suicide Risk Assessment • Comorbidities and Suicide Risk Assessment • Substance Use and Suicide Risk Assessment • Elderly and Suicide Risk Assessment • U.S. Military/Veterans—Primary Care Suicide Risk Assessment • Youth and Suicide Risk Assessment



Recommendations

- Adoption of NQF Measures
 - NQF 0104 – Major Depressive Disorder: Suicide Risk Assessment
 - NQF 1365 – Child and Adolescent Major Depressive Disorder: Suicide Risk Assessment
- Further investigation for endorsement and eSpecification of AHRQ measures:
 - National Quality Measures Clearinghouse (NQMC): 005515 (The Danish National Indicator Project)
- Further development of CQMs for:
 - Additional targeted populations seen in primary care including: substance abuse, other mood disorders, adolescents (specifically those with substance abuse, and patients with certain types of physical illness (e.g., history of myocardial infarction or neurological disease)
 - More specific assessment of suicide “risk” versus ideation



Review	Results
Meaningful Use Stage 1—Final Rule	No measures related to this clinical domain
Meaningful Use Stage 2 (NPRM)	No proposed measures related to this clinical domain
Project Phase 1 eSpecified Measures	No measures related to this clinical domain
Non-endorsed Measures (AHRQ Database)	4 measures related to this clinical domain
Clinical Evidence	48 articles covering 3 broad areas: <ul style="list-style-type: none"> • Post-Traumatic Stress Syndrome (PTSD)Trauma Exposure (Non-Veteran-Specific) • Interpersonal Violence • Childhood Violence/PTSD



Recommendations

- Further investigation for endorsement and eSpecification of measures from the Agency for Healthcare Research and Quality (AHRQ) database identified by their National Quality Measures Clearinghouse (NQMC) numbers and measure stewards below:
 - “Maybe”
 - NQMC: 006322 The Joint Commission (TJC)
 - “Yes”
 - NQMC: 006054 (Veterans Health Administration [VHA])
 - NQMC: 006052 (VHA)
 - NQMC: 001734 Family Violence Prevention Fund
- Future development of CQMs for:
 - Post-traumatic Stress Disorder (PTSD) (Adult/Childhood)
 - Interpersonal Violence



BREAK
10:00a - 10:15a



BREAK-OUT SESSIONS - Morning

10:15 am – 11:30 am

Track 1: Depression (move to Room 733D)

Track 2: Drug Misuse (remain in Room 705A)



BREAK – OBTAIN LUNCH
11:30 am – 12:00 pm



Behavioral Health Clinical Quality Reporting - the Provider Perspective: Incorporating Quality Measures into Practice

Kevin Larsen, MD HHS/ONC

and

Frank Ghinassi, PhD, ABPP
University of Pittsburgh



BREAK-OUT SESSIONS - Afternoon

1:00 pm – 2:15 pm

Track 1: Depression (move to Room 733D)

Track 2: Drug Misuse (remain in Room 705A)



REPORT OUT

2:15 pm – 2:45 pm



BREAK

2:45 pm – 3:00 pm



Karen Pace

National Quality Forum



ADJOURN

Stay connected, communicate, and collaborate



- Browse the ONC website at: healthit.gov
click the Facebook “Like” button to add us to your network
- Contact us at: onc.request@hhs.gov
- Visit the [ONC Newsroom](#) for the latest news and announcements
- Subscribe, watch, and share:



➤  [@ONC HealthIT](https://twitter.com/ONC_HealthIT)

➤  <http://www.youtube.com/user/HHSONC>

➤  [Health IT and Electronic Health Records](#)

➤  <http://www.scribd.com/HealthIT/>

➤  <http://www.flickr.com/photos/healthit>



Health IT Buzz Blog

Putting the I in HealthIT  SM
www.HealthIT.gov